{
    "symbol": "RGLS",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-11 18:51:07",
    "content": " Before we begin, I'd like to remind you that this call will contain forward-looking statements concerning Regulus Therapeutics' future expectations, plans, prospects, corporate strategy and performance, which constitute forward-looking statements for the purpose of the safe harbor provision under the Private Securities Litigation Reform Act of 1995. Following this study, we plan to initiate a Phase 1B multiple ascending dose study in adult patients with ADPKD to assess the safety, tolerability and pharmacokinetics of RGLS8429 treatment, as well as to evaluate the dose response of RGLS8429 on ADPKD biomarkers, including polycystins, cystic kidney volume and overall kidney function."
}